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Abstract
Two series (4 and 5) of diarylpyridine derivatives were designed, synthesized, and evaluated for anti-
HIV-1 activity. The most promising compound, 5e, inhibited HIV-1 IIIB, NL4-3, and RTMDR1 with
low nanomolar EC50 values and selectivity indexes of >10,000. The results of this study indicate that
diarylpyridine can be used as a novel scaffold to derive a new class of potent NNRTIs, active against
both wild-type and drug resistant HIV-1 strains.
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Reverse transcriptase (RT) is one of the most important enzymes in the HIV-1 life cycle. Two
major drug target sites in the RT are the substrate binding site and an allosteric site that is
distinct from, but closely located to, the substrate binding site.1,2,3 Non-nucleoside reverse
transcriptase inhibitors (NNRTIs) interact with the allosteric binding site on HIV-1 RT to cause
distortion of the three-dimensional structure of the enzyme and to inhibit RT catalytic function.
Currently,NNRTIs approved for AIDS therapy include nevirapine, delavirdine, efavirenz, and
etravirine (TMC125). TMC125,4 TMC120,5 a previous clinical candidate, and TMC278,6 a
promising new drug candidate in phase III clinical trial, (Fig 1) are compounds belonging to
the diarylpyrimidine (DAPY) family.7 These compounds are very potent against both wild-
type and many drug-resistant HIV-1 strains. The excellent pharmacological profile of these
compounds has encouraged new research to explore a next-generation of NNRTIs with new
scaffolds. Prior studies on DAPY derivatives have revealed some pharmacophores,1,8 such as
a horseshoe binding conformation, a proper positioning of two phenyl rings in the eastern and
western wings of the NNRT binding pockets, a para-cyanoaniline moiety in the eastern wing,
and two hydrogen bonds to K101 of HIV-1 RT. Based on this SAR information, we initiated
a program to explore new NNRTI leads with new molecular scaffolds and high potency against
wild-type and drug-resistant viral strains. By using an isosteric replacement strategy,
diarylpyridine compounds were designed, synthesized, and evaluated for anti-HIV-1 activity.
Among the tested compounds, new active leads with high potency against both wild-type and
drug-resistant HIV-1 strains were discovered. We report our promising results herein.
Compared to TMC125, our target compounds (Figure 1) were designed to retain the active
para-cyanoaniline moiety, but have a pyridine replacing the pyrimidine ring and various
substituents at the para-position of the phenoxy ring. Because the isosteric replacement of
pyridine for pyrimidine should not change the molecular topology or flexibility, we
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hypothesized that the designed compounds would have similar binding orientation,
conformation, and comparable activity to that of TMC125 and TMC278 (EC50/SI: 0.00158
μM/63,096 and 0.0005 μM/60,000, respectively, against HIV-1IIIB replication in the MT-4 cell
line),9,10 as well as TMC120. However, the substitution of pyridine for pyrimidine resulted in
the loss of an H-bond between K101 and the second nitrogen on the pyrimidine ring. Therefore,
we incorporated a nitro or amino group at the 3-position on the pyridine ring to provide potential
H-bonding with K101, as either an H-bond acceptor or donor.
The target compounds were synthesized via the short routes detailed in Schemes 1 and 2. The
starting material 2,6-dichloro-3-nitropyridine (1) is inexpensive and commercially available.
Reacting 1 with 4-aminobenzonitrile (2) at 140 °C provided 4-(6-chloro-3-nitropyridin-2-
ylamino)benzonitrile (3). Compound 3 was coupled with a substituted phenol in DMF in the
presence of potassium carbonate at 120 °C for 6 h to afford the target compounds 4a-e.
Compound 4f was prepared by Sonogashira coupling11 between 4d and 2-methyl-3-butyn-2-
ol in DMF catalyzed by palladium-copper, and was then refluxed in dry toluene in the presence
of powdered sodium hydroxide to provide 4g (Scheme 2). Finally, the nitro group on the
pyridine ring in 4a-4g was reduced to an amino group by using sodium hydrosulfite
dehydrate12 to afford 5a-5g, respectively (Scheme 1). The spectroscopic data of the 14 target
compounds were consistent with the structures shown in Scheme 1.13
The inhibitory activity of nitro-diarylpyridine (4a-4g) and amino-diarylpyridine (5a-5g)
derivatives on HIV-1 IIIB replication in MT-2 cells and cytotoxicity against MT-2 cells were
determined as previously described.14 As shown in Table 1, except for 4f, most nitro-
substituted compounds (series 4) showed significant inhibitory activity against HIV-1
replication (EC50 0.12 – 2.4 μM) and low cytotoxicity (CC50 50 – 503 μM), resulting in
selectivity index (SI) values of 61 to 4,264. All the amino-substituted compounds (series 5)
displayed greater anti-HIV-1 IIIB activity (EC50 0.001 – 1.58 μM) than the corresponding
compounds in series 4. However, the series 5 compounds were also more cytotoxic (CC50 2.19
– 31.78 μM) than the corresponding series 4 compounds. With an SI of 22,700, the most
promising compound was 5e.
All target compounds were further tested against HIV-1 NL4-3 and a drug resistant strain
HIV-1 RTMDR1, in comparison with TMC120 (Table 2). In agreement with the MT-2 data,
5e was also the most active compound and had the highest SI (13,162) against NL4-3. The
potency of 5e in this assay was comparable to that of TMC120. Interestingly, the active
compounds in both series 4 and 5 showed similar inhibitory potency against NL4-3 and
RTMDR1, which is resistant to many NRTIs and NNRTIs.15 The most potent compound, 5e,
had an EC50 value of 0.96 nM against HIV-1 RTMDR1 and 0.68 nM against HIV-1 NL4-3, a
difference of only 1.4-fold. These results suggested that the pyridine ring is an acceptable
moiety to replace the pyrimidine ring of DAPY compounds and an amino group at the 3-
position of the pyridine ring enhances anti-HIV activity against both wild-type (IIIB and
NL4-3) and multidrug resistant (RTMDR1) HIV-1 strains.
Similar to TMC125, the most active new compound, 5e, has a para-cyano group on the phenoxy
ring. Compounds with methyl, hydroxymethyl, ethynyl, iodo, and no para-substituent were
also active. However, compounds 4f and 5f with a bulky 2-methylbut-3-yn-2-ol [C≡C C(OH)
Me2] group at the para-position of the phenoxy ring lost anti-HIV potency, although 4g and
5g with only a simple ethynyl substituent were active. These results suggested that substituents
at this position of the phenoxy ring also directly affect anti-HIV potency, and a bulky group
might not fit well into the hydrophobic cleft on the west wing of the NNRTI binding site.16
In summary, two series (4 and 5) of diarylpyridine derivatives were designed, synthesized, and
evaluated for anti-HIV-1 activity, resulting in the discovery of a new class of NNRTI leads,
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diarylpyridine-3-amine derivatives (5a — 5e, 5g), with highly potent anti-HIV-1 activity
against both RTI-sensitive (IIIB and NL4-3) and -resistant (RTMDR1) HIV-1 strains. The
most promising compound was 5e, which inhibited HIV-1 IIIB, NL4-3, and RTMDR1 with
low nM EC50 values. The results of this study indicated that diarylpyridine could be used as a
novel scaffold to derive a new class of potent NNRTIs with activity against both wild-type and
drug resistant HIV-1 strains. In addition, the pyridine ring replacement provides a more
convenient and shorter synthetic route, using inexpensive commercial reagents, compared to
the synthesis of DAPYderivatives TMC125 and TMC278.17,10 Our current preliminary
structure-activity relationship (SAR) studies have revealed that (1) the pyridine is an acceptable
isosteric replacement for the pyrimidine ring in DAPY derivatives, (2) an amino group at the
3-position on the pyridine is crucial for enhancing anti-HIV activity, and (3) the R group on
the phenoxy ring is also an important moiety affecting anti-HIV activity. In light of the
promising anti-HIV-1 activity of the diarylpyridine derivatives, further structural optimization
is likely to yield novel NNRTIs with greatly improved potency.
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(a) 140 °C, 4 h, N2, 73%; (b) substituted phenol, K2CO3, DMF, 120 °C, 6 h, 65-82%; (c)
Na2S2O4, NH3·H2O, THF/H2O = 1/1 (v/v), rt, 3h, 41-70%.
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(a) 2-methyl-3-butyn-2-ol, Pd(PPh3)2Cl2, Et3N, CuI, DMF, N2, rt, 7 h, 78%; (b) NaOH,
toluene, reflux, 16 h, 69%.
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Table 1
Inhibitory activity of 4a-4g and 5a-5g on HIV-1IIIB replication in MT-2 cellsa
Compds R CC50 (μM)
b EC50 (μM)
c SId
4a H 110.2±0.0 1.028±0.139 107
4b CH3 503.2±5.2 0.118±0.053 4,264
4c CH2OH 115.8±14.1 0.192±0.005 603
4d I 148.5±31.2 2.428±0.309 61
4e CN 50.13±2.60 0.135±0.286 371
4f C≡CC(OH)Me2 8.91±0.0 23.28±10.48 <1
4g C≡CH 173.6±46.0 0.677±0.286 256
5a H 29.9±2.3 0.576±0.182 52
5b CH3 10.55±0.41 0.058±0.026 182
5c CH2OH 2.19±0.41 0.006±0.002 391
5d I 23.49±5.77 0.079±0.007 297
5e CN 31.78±10.37 0.0014±0.0023 22,700
5f C≡CC(OH)Me2 3.54±1.07 1.578±0.097 2
5g C≡CH 8.25±0.51 0.424±0.282 20
a
Compounds were tested in triplicate and the data are presented as means ± SD.
b
XTT assay was used to determine the 50% cytotoxic concentration (CC50).
c
ELISA was used to determine p24 production, based on which the 50% effective concentration (EC50) for inhibiting HIV-1 replication was calculated.
d
Selectivity index (SI) = CC50/ EC50
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